A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
This phase I clinical trial is the first study to evaluate the feasibility and safety of administering enoblituzumab to pediatric patients with relapsed solid tumors. We demonstrated that B7-H3 is highly expressed across a wide variety of tumor histologies. Enoblituzumab could be safely administered at a dose of 15 mg/kg. However, no objective responses were observed, suggesting that alternative strategies to target B7-H3 for children with relapsed tumors should be considered.
Authors
- John M. Maris (ORCID: https://orcid.org/0000-0002-8088-7929)
- Paul M. Sondel (ORCID: https://orcid.org/0000-0002-0981-8875)
- Julie R. Park (ORCID: https://orcid.org/0000-0002-6777-9165)
- Rosandra N. Kaplan (ORCID: https://orcid.org/0000-0002-8580-0001)
- Meenakshi Hegde (ORCID: https://orcid.org/0000-0002-7778-7871)
- Kenneth B. DeSantes (ORCID: https://orcid.org/0000-0002-9092-0139)
- Crystal L. Mackall (ORCID: https://orcid.org/0000-0003-0359-9023)
- Paul R. Hutson (ORCID: https://orcid.org/0000-0002-6968-7096)
- Kimberly A. McDowell (ORCID: https://orcid.org/0009-0000-5412-105X)
Institutions
- National Institutes of Health (US)
- St. Jude Children's Research Hospital (US)
- Children's Hospital of Philadelphia (US)
- University of Wisconsin–Madison (US)
- Baylor College of Medicine (US)
- University of Wisconsin Carbone Cancer Center (US)
- Children's Health Council (US)
- Seattle Children's Hospital (US)
- University of Wisconsin American Family Children's Hospital (US)
- National Cancer Institute (US)
- Children's Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0293
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- American Association for Cancer Research
- MacroGenics
- National Institutes of Health
- Stand Up To Cancer